Cost comparisons by state.
The German pharmaceutical market still looks inviting to drug manufacturers. Germany has one of the highest levels of health care spending in the world and has the largest pharmaceutical market in Europe. (Source: United BioSource Corp. “Evidence Matters” Newsletter, Oct 2010)
A Prescription for Change: How the Medicare Act Revises Hatch-Waxman to Speed Market Entry of Generic Drugs
The author reviews the pharmaceutical industry's patenting process as it has been impacted by the Hatch-Waxman and Medicare legislation which expedite review and approval for generic follow-on drugs. (Source: Jnl Corporation Law, Winter 2005, last revised Oct 2009)
A View from Washington: Federal Policy in Relation to Allied Health Over Two Decades, by Thomas Elwood
In a series of 31 essays originally published in the Journal of Allied Health over a 20-year period, this book surveys the development of federal health policy as it relates to allied health.
One major change in the structure of the national health insurance started in 2002, when a Universal Coverage (UC) health insurance policy was launched. (Source:ISPOR Connections, Sept/Oct 2010, page 11)
Agency mission is to improve the quality, safety, efficiency, and effectiveness of health care for all Americans.
Part of the US Dept of HHS that conducts public health assessments, health studies, and health surveillance for those exposed to hazardous materials, and maintains exposure and disease registries for long- term follow-up or specific scientific studies. ATSDR analyzes the statistical significance of human disease, biomarkers, and other health outcomes in the presence of environmental contamination to establish possible relationships between exposure and health.
This fact sheet describes awards made by the Agency for Healthcare Research and Quality (AHRQ) in Fiscal Year (FY) 2010 to support trainees who are focusing on comparative effectiveness research. Funding to support these projects was provided through the American Recovery and Reinvestment of 2009.
Variety of White Papers, News, Methods Guides, and Databases to facilitate Comparative Effectiveness.
The State Snapshots provide State-specific health care quality information, including strengths, weaknesses, and opportunities for improvement. The goal is to help State officials and their public- and private-sector partners better understand health care quality and disparities in their State.
The Alliance for Health Policy and Systems Research is an international collaboration based in the WHO Geneva. It aims to promote the generation and use of health policy and systems research as a means to improve the health systems of developing countries.
Article examins the attempt to develop a robust and defensible means of measuring and describing the degree of patient access in mixed NICE decisions.(Source: Pharmacoeconomics, O'Neill et al)
Report from the Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) Research Network.
Contains links to National Health Insurance in Taiwan, development of the healthcare system in Taiwan, and more.
The Canadian Agency for Drugs and Technologies in Health (CADTH) provides decision-makers with the evidence, analysis, advice, and recommendations they require to make informed decisions in health care.
Provides data on morbidity, epidemiological surveillance of infectious diseases, chronic diseases, occupational diseases and injuries, vaccine efficacy, and safety.
Only 32% of medication studies published in top medical journals compared the effectiveness of existing treatments, and active-comparator trials were less likely than trials with inactive controls to report positive results. (Source: Michael Hochman, MD; Danny McCormick, MD, MPH, JAMA, 2010;303(10):951-958)
Although geographic differences in Medicare spending are widely considered to be evidence of program inefficiency, policymakers need to understand how differences in beneficiaries' health and personal characteristics and specific geographic factors affect the amount of Medicare spending per beneficiary before formulating policies to reduce geographic differences in spending. (Source: NEJM, July 2010)
Closing the Quality Gap Series. Through the Quality Kaleidoscope: Reflections on the Science and Practice of Improving Health Care Quality
AHRQ Report summarizes the knowledge of eight Evidence-based Practice Centers (EPCs) to synthesize lessons learned and to advance the state of QI science. Includes effectiveness of bundled payment programs, patient-centered medical home, adherence interventions, and public reporting, as well as QI strategies to address health disparities, prevention of healthcare-associated infections, QI measurement of disabilities, and for patients with advanced and serious illness.
CPI database, inflation calculator, etc. The Consumer Price Indexes (CPI) program produces monthly data on changes in the prices paid by urban consumers for a representative basket of goods and services.
Annual Demographic Survey (March CPS Supplement) includes health insurance coverage.
Includes updated guidance documents
A compilation of information about virtually all major data collection systems sponsored by the U.S. Department of Health and Human Services
Focusing on scientific cooperation in HTA in Europe, thirty four government appointed organisations from the EU Member States, Accession Countries and EEA work together to help developing reliable, timely, transparent and transferable information to contribute to HTAs in European countries. The EUnetHTA Joint Action builds on the achievements of a number of the previous European initiatives including the EUnetHTA Project (2006-2008) and the Pharmaceutical Forum (on relative effectiveness).
AHRQ Project designed to strengthen the science base of quality measurement while expanding the scope and availability of validated, ready-to-use measures. Q-SPAN builds on past work in quality measurement by public and private organizations through eight cooperative agreements to develop and test additional clinical performance measures for specific conditions, patient populations, and health care settings.
The FastStats site provides quick access to statistics on topics of public health importance and is organized alphabetically. Links are provided to publications that include the statistics presented, to sources of more data, and to related web pages.
The Code of Federal Regulations (CFR) is a codification of the general and permanent rules published in the Federal Register by the Executive departments and agencies of the Federal Government.
FDA Final Guidance on Patient-Reported Outcome (PRO) Measures: Use in Medical Product Development to Support Labeling Claims
FDA released the Final Guidance for Industry Patient-Reported Outcome Measures: United BioSource Corp Analysis
UBC provides analysis and summary of this guidance.
Gateway to statistics from over 100 agencies. Sort by health and get links to AHRQ, CDC, CMS, etc. etc.
Finding and Using Health Statistics: A Self Study Course** - National Information Center on Health Services Research & Health Care Technology (NICHSR)
A very useful interactive tutorial.
Press releases, backgrounders, meeting calendars, etc.
This book examines the advantages and disadvantages of funding arrangements currently in use across Europe. Adopting a cross-national, cross-disciplinary perspective, it assesses the relative merits of the main methods of raising resources including taxation; social, voluntary and supplemental forms of insurance; and self-pay including co-payments. There is a cost to purchase this book. (Source: New Jersey Long Term Care Insurance, July 27, 2010)
The government has unveiled its plans for a new outcomes framework to underpin the revamped National Health Service and establish accountability at a national level “in an open and transparent way”. The NHS Outcomes Framework will consist of a set of national outcome goals to help give an indication of the overall performance of the Service, as well as provide a mechanism by which the Health Secretary can hold the new independent NHS Commissioning Board to account for securing improved health outcomes. (Source: Pharma Times July 20, 2010)
In partnership with provincial and territorial governments, Health Canada provides national leadership to develop health policy, enforce health regulations, promote disease prevention and enhance healthy living for all Canadians.
AHRQ's Technology Assessment program uses state-of-the-art methodologies for assessing clinical utility of medical interventions.
Is unneeded surgery costing NHS millions? The Health Service Journal of the UK says "yes". Patient-reported outcome measures (PROMs) are required and public hospital ratings based on PROMs available by November 2009.
"Healthcare 411" is a new series produced by AHRQ with podcasts and other information to assist consumers with taking charge of the quality of their healthcare.
Downloadable file includes 26 objectives based on mortality data. State-level mortality for five population subgroups; Numbers of deaths. Data are also presented for HIV-related mortality.
Provides vital event, demographic, social, and economic statistics on American Indians and Alaska Natives living in IHS service areas, as well as patient care and morbidity information for those who use IHS services.
This publication presents overviews of the health care systems of 13 countries—Australia, Canada, Denmark, England, France, Germany, Italy, the Netherlands, New Zealand, Norway, Sweden, Switzerland, and the United States. A summary table presents information on population, health care spending, number of physicians, hospital spending and utilization, use of health information technology, and number of potentially avoidable deaths.
It is worth asking “Why Medicaid?” Why not simply subsidize all poor people who do not qualify for Medicaid under current standards and enroll them in health insurance exchanges? (Source: Sara Rosenbaum, J.D., NEJM, Oct. 14, 2009)
The Swedish authority for registration of new drugs. Like FDA but in Sweden.
Learning resource for professionals interested in Medicare Advantage, Medicare Prescription Drug Plans, and related programs.
As the United States' principal health statistics agency, we compile statistical information to guide actions and policies to improve the health of our people.
The National Centre for Pharmacoeconomics conducts the health technology assessment (HTA) of pharmaceutical products for the Health Service Executive (HSE) in Ireland in collaboration with the HSE Corporate Pharmaceutical Unit (HSE-CPU). The aim of the centre is to promote expertise in Ireland for the advancement of the discipline of pharmacoeconomics through practice, research and education.
The National Institute for Health and Clinical Excellence (NICE) will have existed for 10 years on April 1, 2009.(Source: The Lancet Oncology, Volume 10, Issue 4, Pages 417 - 424, April 2009)
Coverage, performance data, policy updates, etc.
Presentation at ISPOR Europe, Nov. 2011
Presentation at ISPOR Europe, Nov. 2011
M. Sculpher, MSc, PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK, PPT Presentation: "Pros and Cons of a Centralized European Pricing and Reimbersement Agency"
The statement's provocative recommendations include the imposition of requirements that (a) the off-label drug should be "irreplaceable for treatment of the patient," that is, no drug labeled for the indication is available; (b) the off-label use must be "submitted and approved by the hospital's pharmacotherapy committee and hospital ethics committee" except in emergency situations; and (c) informed consent for off-label use must be obtained from the patient or a legal representative. (Source: JMCP October 2010 Volume 16 Issue 8, Authors: Kathleen A. Fairman, MA, and Frederic R. Curtiss, PhD, RPh, CEBS)
Selecting quality of care and resource use measures is an important and challenging task for organizations striving to improve the quality of health care in their communities. This Decision Guide is designed to inform readers about the most critical issues to consider when selecting and adopting such performance measures.
Single Technology Appraisal at the UK National Institute for Health and Clinical Excellence: A Source of Evidence and Analysis for Decision Making Internationally
Pay for view article by Sculpher in PharmacoEconomics.(Source: PharmacoEconomics, 2010, vol. 28, issue 5, pages 347-349)
Self study education course from National Information Center on Health Services Research and Health Care Technology (NICHSR). Goals of module include: 1) the significant trends in spending, outcomes, and access within the U.S. health care system; and; 2)the main sources of literature and data relating to health care financing in the U.S.
Prepared for Congress December 2007.
University of Michigan Library - A statistical portal. Links to health stats (example, Deaths; disability; Health Care; Health Insurance; HMOs; International Life Tables; Prescription Drugs; Social Security Death Index; Surgery; transplants; Vital Statistics, etc.) Demographics: population, race, ethnicity, etc.
GfK HealthCare, one the largest providers of fully integrated custom health care marketing research in the world, announced today the undertaking of a first-ever research study aimed at examining the UK's National Institute for Health and Clinical Excellence (NICE) as a model producer of Health Technology Appraisals (HTA), and its impact on decision making in ex-UK health care systems. (Source: The Medical News, July 21, 2010)
The program created to provide Medicare recipients with prescription drug benefits exceeded expectations during its first two years, extending pharmacy coverage to most seniors while reducing their overall spending on drugs, according to a new RAND Corporation study. (Source: RAND, Aug. 2009)
(SAMHSA) in the Dept of Health and Human Services (HHS) provides information on health problems related to the use and abuse of drugs and alcohol (the Center for Substance Abuse Prevention); substance abuse treatment (the Center for Substance Abuse Treatment); the mental health condition of the population (the Center for Mental Health Services); and the prevalence and incidence of substance abuse and its medical impact (the Office of Applied Studies).
What are the basic details of the 2012 Medicare Part D Program? Which governmental agency is responsible for the Medicare Part D program? How many Medicare Part D plans are currently available? Where did the Medicare Part D prescription drug program come from?
The European Medicines Agency Road Map to 2015: The Agency’s Contribution to Science, Medicines, Health
The European Medicines Agency has launched a three-month public consultation on its draft of The Road Map to 2015: The Agency's Contribution to Science, Medicines, Health with comments due by April 30, 2010. (Source: European Medicines Agency, Jan. 2010)
HHS State Report has recently been issued, including statistics on health care cost and quality for each of the 50 states in US. Examples include % increase in health premiums, costs of care for uninsured, % of state residents without health insurance, and quality ratings.
The market structure of the U. S. health industry not only reflects the nature of health care, but also its origins in the 1930's and its evolution in succeeding decades. This report discusses how the current health insurance market structure affects the two policy goals of expanding insurance coverage and containing health care costs. (Source: D. Andrew Austin and Thomas L. Hungerford, weSRCH, Nov. 17, 2009)
Shelby D. Reed, PhD, Associate Professor, Duke Clinical Research Institute, Durham, NC, USA; Scott Ramsey, PhD, MD, Member, Fred Hutchinson Cancer Research Center & Professor, School of Medicine, University of Washington, Seattle, WA, USA; Michael Iskedjian, MSc, President, PharmIdeas Research and Consulting and Professor, Université de Montréal, Montréal, QC, Canada; John O'Donnell, PhD, MA, Vice President, Global Health Economics and Outcomes Research, Bristol-Myers Squibb Company, Princeton, NJ, USA, ISPOR Washington DC, 2012.
BBC Documentary "The Price of Life" discussed NICE and is causing much controversy.
AHRQ Report, prepared August 2009, to help inform CMS if there is a causal relationship between the timing of initiating coverage for new technology and beneficiary participation in clinical trials to provide evidence of effectiveness.
June 2009, the new commissioner of the Food and Drug Administration (FDA), Dr. Margaret Hamburg, announced a major transparency initiative. The goal of this initiative was to better explain the FDA’s actions by providing information that supports clinical medicine, biomedical innovation, and public health. (Source: The New England Journal of Medicine, May 19, 2010)
Downloadable files on demographics, maps, etc.
The pioneering and influential National Institute for Health and Clinical Excellence (NICE) in London currently assesses drugs and decides whether they are cost-effective and should be available through the country's National Health Service (NHS). But the coalition government is making plans to pay drug companies only what a medicine is worth, promising to shake up the industry — and it is not yet clear what part NICE will play in the new system.(Source: Naturenews)
Value-based pricing for pharmaceuticals: Its role, specification and prospects in a newly devolved NHS
In December 2010, the Government launched its consultation on its plans to change the way medicines are priced in the UK. By 2014, a system of ‘value-based pricing’ (VBP) will replace the current Pharmaceutical Price Regulation Scheme (PPRS), which is a voluntary agreement between the Department of Health (DH) and the pharmaceutical industry whereby companies negotiate profit rates from drug sales to the National Health Service (NHS) every 5 years utilising price and profit controls.
The new value-based pricing strategy will radically overhaul the way medicines are paid for. Once the PPRS scheme has run its course by 2014, grug prices will be set according to the value the medicines provide. The White Paper also proposes changes to the role of NICE (National Institute of Clinical Excellence) and structural shifts in the way that budgets are managed – with 80% of control being handed over to GP’s. (Source: InPharm.)
Health Economics Tools for Financial Management of Public Hospitals Networks. (Source: WHO Collaborating Centre on Health Economics and Pharmaceutical Policies, www.who.int)